Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is poised for success due to its high-impact technologies and strong partnerships with medical device companies, leading to a positive outlook for its stock. The company's robust pipeline, which includes AVIM therapy and Virtue SAB, shows great potential for addressing major cardiovascular diseases and achieving commercial success. Despite potential risks such as product failure and dependence on commercial partners, the company's healthy cash position and upcoming pivotal trials make it a strong investment opportunity.

Bears say

Orchestra BioMed Hldgs is a biomedical company that has its sights on revolutionizing healthcare through innovative technologies. However, the company has faced numerous challenges, including a history of losses and the need for continuous external funding. Additionally, the company's limited human clinical data for its product candidates may pose a significant barrier to their success. Despite the potential of its products, competition in the market and the company's dependence on commercial partners also present risks.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.